Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Urolithin A for Alzheimer’s Disease
Dona Pamoda W. Jayatunga, Eugene Hone, Harjot Khaira, et al.
Nutrients (2021) Vol. 13, Iss. 11, pp. 3744-3744
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

The Impact of Ellagitannins and Their Metabolites through Gut Microbiome on the Gut Health and Brain Wellness within the Gut–Brain Axis
Roxana Banc, Marius Emil Rusu, Lorena Filip, et al.
Foods (2023) Vol. 12, Iss. 2, pp. 270-270
Open Access | Times Cited: 50
The Potential of Flavonoids and Flavonoid Metabolites in the Treatment of Neurodegenerative Pathology in Disorders of Cognitive Decline
James Melrose
Antioxidants (2023) Vol. 12, Iss. 3, pp. 663-663
Open Access | Times Cited: 42
Ellagitannins, urolithins, and neuroprotection: Human evidence and the possible link to the gut microbiota
Rocío Garcı́a-Villalba, Francisco A. Tómas‐Barberán, Carlos E. Iglesias‐Aguirre, et al.
Molecular Aspects of Medicine (2022) Vol. 89, pp. 101109-101109
Open Access | Times Cited: 50
Are mitophagy enhancers therapeutic targets for Alzheimer’s disease?
Jangampalli Adi Pradeepkiran, Ashly Hindle, Sudhir Kshirsagar, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 149, pp. 112918-112918
Open Access | Times Cited: 40
Mitophagy: A promising therapeutic target for neuroprotection during ageing and age‐related diseases
Ela Mishra, Mahendra Kumar Thakur
British Journal of Pharmacology (2023) Vol. 180, Iss. 12, pp. 1542-1561
Closed Access | Times Cited: 37
Interactions between Gut Microbiota and Polyphenols: New Insights into the Treatment of Fatigue
Chuanhong Luo, Xichuan Wei, Jiao Song, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7377-7377
Open Access | Times Cited: 30
The emerging role of autophagy and mitophagy in tauopathies: From pathogenesis to translational implications in Alzheimer’s disease
Xiao‐Lan Liu, Meng Ye, Liang Ma
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 28
Urolithin A exhibits a neuroprotective effect against Alzheimer’s disease by inhibiting DYRK1A activity
Huang‐Ju Tu, C SU, Chao-Shiang Peng, et al.
Journal of Food and Drug Analysis (2023) Vol. 31, Iss. 2, pp. 358-370
Open Access | Times Cited: 17
Glucagon-like Peptide 1 Receptor Activation Inhibits Microglial Pyroptosis via Promoting Mitophagy to Alleviate Depression-like Behaviors in Diabetic Mice
Fan Yang, Xin‐shang Wang, Jingyu Qi, et al.
Nutrients (2022) Vol. 15, Iss. 1, pp. 38-38
Open Access | Times Cited: 27
Mitochondrion: A bridge linking aging and degenerative diseases
Lanlan Zhang, Jianlong Wu, Ziguan Zhu, et al.
Life Sciences (2023) Vol. 322, pp. 121666-121666
Open Access | Times Cited: 15
The Mitochondrion: A Promising Target for Kidney Disease
Cem Tanrıöver, Sidar Çöpür, Duygu Uçku, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 570-570
Open Access | Times Cited: 13
Luteolin attenuates LPS-induced damage in IPEC-J2 cells by enhancing mitophagy via AMPK signaling pathway activation
Ji‐hang Yuan, Ke Zhang, Lingling Yang, et al.
Frontiers in Nutrition (2025) Vol. 12
Open Access
The Protective Effect of Ellagic Acid and Its Metabolites Against Organ Injuries: A Mitochondrial Perspective
Sohrab Rahmani, Ali Roohbakhsh, Yazdan Hasani Nourian, et al.
Food Science & Nutrition (2025) Vol. 13, Iss. 4
Open Access
Ellagic Acid: A Dietary-Derived Phenolic Compound for Drug Discovery in Mild Cognitive Impairment
Wenjun Wang, Shaohui Wang, Yue Liu, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 20
Inner mitochondrial membrane protein Prohibitin 1 mediates Nix-induced, Parkin-independent mitophagy
Kibrom M. Alula, Yaritza Delgado‐Deida, Rosemary Callahan, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases
Germán Plascencia‐Villa, George Perry
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12486-12486
Open Access | Times Cited: 10
Pharmacological Effects of Urolithin A and Its Role in Muscle Health and Performance: Current Knowledge and Prospects
Haotian Zhao, Ge Song, Hongkang Zhu, et al.
Nutrients (2023) Vol. 15, Iss. 20, pp. 4441-4441
Open Access | Times Cited: 10
Physiologically‐Based Pharmacokinetic Modeling of the Postbiotic Supplement Urolithin A Predicts its Bioavailability Is Orders of Magnitude Lower than Concentrations that Induce Toxicity, but also Neuroprotective Effects
Georg Aichinger, Maja Stevanoska, Karsten Beekmann, et al.
Molecular Nutrition & Food Research (2023) Vol. 67, Iss. 15
Open Access | Times Cited: 9
Role of mitophagy in the neurodegenerative diseases and its pharmacological advances: A review
Qixia Wang, Haoyuan Xue, Yun-Di Yue, et al.
Frontiers in Molecular Neuroscience (2022) Vol. 15
Open Access | Times Cited: 15
Walnut polyphenols and the active metabolite urolithin A improve oxidative damage in SH-SY5Y cells by up-regulating PKA/CREB/BDNF signaling
Lei An, Mengxue Li, Cunen Zou, et al.
Food & Function (2022) Vol. 14, Iss. 6, pp. 2698-2709
Closed Access | Times Cited: 14
Natural products for kidney disease treatment: Focus on targeting mitochondrial dysfunction
Jiewu Huang, Ye Liang, Lili Zhou
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Urolithin A in Health and Diseases: Prospects for Parkinson’s Disease Management
Olga Wojciechowska, Małgorzata Kujawska
Antioxidants (2023) Vol. 12, Iss. 7, pp. 1479-1479
Open Access | Times Cited: 8
Pomegranate polyphenol punicalagin as a nutraceutical for mitigating mild cognitive impairment: An overview of beneficial properties
Wenjun Wang, Pan Long, Mengshan He, et al.
European Journal of Pharmacology (2024) Vol. 977, pp. 176750-176750
Closed Access | Times Cited: 2
Pomegranate (Punica granatum L.) Extract Effects on Inflammaging
Raffaele Cordiano, Luca Gammeri, Eleonora Di Salvo, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 4174-4174
Open Access | Times Cited: 2
Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome
Laurent Meijer, Emilie Chrétien, Denis Ravel
Journal of Alzheimer s Disease (2024) Vol. 101, Iss. s1, pp. S95-S113
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top